<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206400</url>
  </required_header>
  <id_info>
    <org_study_id>pioglitazonetestosterone</org_study_id>
    <nct_id>NCT01206400</nct_id>
  </id_info>
  <brief_title>Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study</brief_title>
  <official_title>Effect of Pioglitazone on Testosterone in Eugonadal Men With Type 2 Diabetes Mellitus - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of pioglitazone on the steroidogenic enzyme axis in eugonadal men with
      type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several clinical studies demonstrated that pioglitazone not only improves insulin sensitivity
      but also decreases plasma androgen concentrations (DHEAS and androstenedione) in women with
      polycystic ovary syndrome (PCOS) . However the reduction in the androgen levels in PCOS is
      whether secondary to increase in the insulin sensitivity or due to direct effect of
      thiazolidinediones on steroidogenesis is not known.So far, two human studies have been
      conducted regarding the effects of rosiglitazone (a thiazolidinedione group of drug) on
      testosterone level, one in healthy individuals and another was in patients of type 2 diabetes
      with hypogonadism . But these studies gave equivocal results as the study population were
      different. Hence we plan to study the effects of pioglitazone on the steroidogenic enzyme
      axis in eugonadal men with type 2 diabetes mellitus.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pioglitazone effect on testosterone level</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>pioglitazone vs placebo</arm_group_label>
    <description>15 patients in pioglitazone group and 15 in placebo group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        30 eugonadal men with type 2 diabetes mellitus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c level of 7.5% or less on stable dosages of sulphonylurea (glimepiride 1-6mg/day)
             and metformin (1-2g/day) for at least six weeks and BMI of 20-30 kg/m2.

        Exclusion Criteria:

          -  hepatic impairment, coronary artery disease and or heart failure, renal failure, those
             who requires insulin therapy or HbA1c &gt;7.5%, presence of macular edema and serum
             albumin &lt;3gm/dL.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Anil Bhansoli, MD.DM</last_name>
    <role>Study Chair</role>
    <affiliation>PGIMER,Chandigarh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>sridhar subbiah, MD medicine</last_name>
    <phone>9914411026</phone>
    <email>drsridharjipmer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr anil Bhansoli, MD.DM</last_name>
    <phone>9316977995</phone>
    <email>anilbhansali_endocrine@rediffmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr sridhar subbiah, MD</last_name>
      <phone>9914411026</phone>
      <email>drsridharjipmer@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Anil Bhansali, MD.DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Kapoor D, Channer KS, Jones TH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res. 2008 Jun;5(2):135-7. doi: 10.3132/dvdr.2008.022.</citation>
    <PMID>18537102</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <last_update_submitted>June 28, 2011</last_update_submitted>
  <last_update_submitted_qc>June 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr SRIDHAR</name_title>
    <organization>PGIMER</organization>
  </responsible_party>
  <keyword>eugonadal, testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

